Reaction
Mastectomy reporting signals
As of the last recalculation, Mastectomy appears in 1,723 FAERS reports alongside 37 co-occurring drug terms. The strongest observed disproportionality signal is CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE (PRR 49.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Conjugated Estrogens And Medroxyprogesterone Acetate | 92 | 49.7 | 49.9 |
| Pertuzumab | 75 | 34.8 | 34.9 |
| Medroxyprogesterone Acetate | 116 | 30.1 | 30.2 |
| Conjugated Estrogens | 112 | 24.8 | 24.8 |
| Estrogens, Conjugated | 112 | 24.3 | 24.3 |
| Ado-Trastuzumab Emtansine | 16 | 23.1 | 23.2 |
| Trastuzumab | 119 | 22.4 | 22.5 |
| Anastrozole | 51 | 17.3 | 17.3 |
| Niraparib | 31 | 17.2 | 17.2 |
| Doxepin | 13 | 15.6 | 15.6 |
| Alendronate Sodium | 111 | 14.1 | 14.1 |
| Letrozole | 68 | 13.8 | 13.9 |
| Doxepin Hydrochloride | 13 | 12.5 | 12.5 |
| Letrozole Tablets | 46 | 11.8 | 11.9 |
| Lanreotide Acetate | 6 | 9.3 | 9.3 |
| Anastrozole Tablets | 16 | 9.1 | 9.1 |
| Palbociclib | 64 | 8.4 | 8.4 |
| Bosentan | 34 | 8.3 | 8.3 |
| Estradiol | 55 | 7.9 | 7.9 |
| Lapatinib | 10 | 7.8 | 7.8 |
| Paclitaxel (Aibumin-Bound) | 50 | 7.5 | 7.5 |
| Docetaxel Anhydrous | 40 | 7.3 | 7.3 |
| Docetaxel | 40 | 7.3 | 7.3 |
| Pembrolizumab | 59 | 7.0 | 7.0 |
| Paclitaxel | 51 | 6.4 | 6.4 |
| Calcium, Magnesium, Potassium, And Sodium Oxybates | 4 | 5.6 | 5.6 |
| Rucaparib | 4 | 5.5 | 5.5 |
| Carboplatin | 54 | 5.3 | 5.3 |
| Fam-Trastuzumab Deruxtecan-Nxki | 4 | 4.8 | 4.8 |
| Risankizumab-Rzaa | 31 | 4.6 | 4.6 |
| Ranolazine | 4 | 4.6 | 4.6 |
| Olaparib | 8 | 4.6 | 4.6 |
| Pegfilgrastim | 35 | 4.4 | 4.4 |
| Umeclidinium Bromide And Vilanterol Trifenatate | 6 | 4.4 | 4.4 |
| Belimumab | 11 | 4.2 | 4.2 |
| Bimekizumab | 4 | 2.3 | 2.3 |
| Esketamine Hydrochloride | 3 | 2.0 | 2.0 |